BioNxt Solutions (TSE:BNXT)
:BNXT
Top Page
BioNxt Solutions
(BNXT)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.58
▼(-10.00% Downside)
Action:ReiteratedDate:01/14/26
The score is driven mainly by very weak financial performance (losses, negative equity, rising debt, and ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD). Valuation is difficult to assess given negative earnings and no dividend support, providing limited offset.
Positive Factors
Reduced cash burn trend
The company reports that losses and cash burn have moderated versus the weakest 2021–2022 period. A sustained reduction in cash outflow pace can extend runway, lower near-term refinancing pressure, and provide management time to execute restructuring or commercialization plans.
Negative Factors
Negative shareholders' equity
Negative equity denotes solvency pressure and limited balance sheet flexibility. It raises refinancing and dilution risk, constrains access to conventional credit, and signals that accumulated losses have materially eroded investor capital—impairing long‑term financial resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Reduced cash burn trend
The company reports that losses and cash burn have moderated versus the weakest 2021–2022 period. A sustained reduction in cash outflow pace can extend runway, lower near-term refinancing pressure, and provide management time to execute restructuring or commercialization plans.
Read all positive factors
BioNxt Solutions (BNXT) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$64.56M
Dividend YieldN/A
Average Volume (3M)80.86K
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue Growth-62.34%
EPS Growth9.80%
CountryCA
Employees25
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding121,810,260
10 Day Avg. Volume59,081
30 Day Avg. Volume80,860
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)-5.39
Price to Sales (P/S)1568.84
P/FCF Ratio-13.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BioNxt Solutions Business Overview & Revenue Model
Company Description
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medication...
How the Company Makes Money
BioNxt Solutions generates revenue through a multi-faceted approach that includes the sale of proprietary diagnostic assays and biopharmaceutical products. The company earns income from direct product sales to healthcare providers and research ins...
BioNxt Solutions Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.82K | 26.98K | 372.25K | 297.44K | 286.50K | 345.65K |
| Gross Profit | -12.51K | 26.98K | 372.25K | 195.62K | 199.48K | 345.65K |
| EBITDA | -4.95M | -4.32M | -6.48M | -11.51M | -19.19M | -16.05M |
| Net Income | -6.18M | -5.31M | -7.72M | -12.38M | -20.64M | -16.89M |
Balance Sheet | ||||||
| Total Assets | 1.23M | 569.36K | 1.27M | 1.61M | 9.73M | 8.28M |
| Cash, Cash Equivalents and Short-Term Investments | 468.76K | 32.35K | 363.65K | 136.20K | 1.35M | 2.58M |
| Total Debt | 8.33M | 4.28M | 4.89M | 4.37M | 5.46M | 3.31M |
| Total Liabilities | 9.54M | 8.43M | 6.55M | 5.74M | 8.06M | 4.28M |
| Stockholders Equity | -8.31M | -7.86M | -5.28M | -4.13M | 1.67M | 4.01M |
Cash Flow | ||||||
| Free Cash Flow | -5.18M | -3.03M | -5.37M | -6.23M | -12.61M | -10.36M |
| Operating Cash Flow | -5.18M | -3.03M | -5.17M | -6.23M | -12.16M | -10.20M |
| Investing Cash Flow | 83.63K | 56.21K | 100.84K | -3.86K | -5.31M | -156.47K |
| Financing Cash Flow | 5.49M | 2.64M | 5.29M | 5.02M | 16.23M | 12.65M |
BioNxt Solutions Technical Analysis
Negative
0.64
Price Trends
0.58
Negative
0.62
Negative
0.70
Negative
Market Momentum
-0.02
Positive
40.86
Neutral
48.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BNXT, the sentiment is Negative. The current price of 0.64 is above the 20-day moving average (MA) of 0.58, above the 50-day MA of 0.58, and below the 200-day MA of 0.70, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 40.86 is Neutral, neither overbought nor oversold. The STOCH value of 48.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BNXT.
BioNxt Solutions Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$56.36M | -2.79 | -19.76% | ― | 26.91% | 81.01% | |
46 Neutral | C$18.85M | -5.08 | -68.32% | ― | 2.41% | 74.61% | |
46 Neutral | C$29.65M | -6.72 | -71.80% | ― | -3.94% | -17.62% | |
45 Neutral | C$27.35M | -3.68 | -19.10% | ― | 18.06% | 34.58% | |
42 Neutral | C$64.56M | -16.32 | ― | ― | -62.34% | 9.80% |
* Healthcare Sector Average
TSE:BNXT
BioNxt Solutions
0.53
-0.01
-1.85%
TSE:ATLE
Willow Biosciences Inc
0.16
0.11
226.53%
TSE:QNTM
Quantum Biopharma
6.57
-4.56
-40.97%
TSE:LABS
MediPharm Labs
0.07
-0.04
-35.00%
TSE:AVCN
Avicanna
0.15
-0.16
-50.82%
TSE:INNO
InnoCan Pharma
6.59
-6.73
-50.54%
BioNxt Solutions Corporate Events
Business Operations and StrategyPrivate Placements and Financing
BioNxt Moves to Retire $2.7 Million in Debenture Debt via Share Issuance
Neutral
Jan 23, 2026
BioNxt Solutions Inc. has proposed a shares-for-debt transaction with arm’s length creditors to extinguish approximately $2.7 million in outstanding obligations arising from 8% convertible debentures issued in December 2022. In full settleme...
Business Operations and StrategyProduct-Related Announcements
BioNxt’s Sublingual Cladribine Film Delivers 40% Higher Exposure in Preclinical MS Study
Positive
Jan 21, 2026
BioNxt Solutions has reported final results from a preclinical study in miniature pigs showing that its proprietary sublingual oral dissolvable film formulation of cladribine for multiple sclerosis achieved approximately 40% higher systemic drug e...
Business Operations and StrategyProduct-Related Announcements
BioNxt’s Cladribine Film Shows Superior Bioavailability in Preclinical MS Study
Positive
Jan 20, 2026
BioNxt Solutions has reported successful results from a comparative pharmacokinetics study in pigs showing that its proprietary sublingual cladribine orally dissolving film delivers superior bioavailability versus the standard name-brand tablet us...
Business Operations and StrategyProduct-Related Announcements
BioNxt Advances Thin-Film Drug Platform With First Patent for Sublingual Cladribine
Positive
Jan 20, 2026
BioNxt Solutions has reported significant progress in developing its proprietary rapid-dissolving, “melt-in-your-mouth” thin-film drug delivery platform to address dysphagia, a widespread problem that affects up to 40% of adults and ne...
Business Operations and StrategyProduct-Related Announcements
BioNxt Signs Agreement for Sublingual Chemotherapy and Immunosuppressant Innovation
Positive
Dec 17, 2025
BioNxt Solutions Inc. has entered into a letter agreement to co-develop a novel sublingual drug formulation for chemotherapy and immunosuppressant treatments, securing exclusive intellectual property rights in collaboration with a European-based c...
Business Operations and StrategyProduct-Related Announcements
BioNxt Secures Eurasian Patent for Sublingual Cladribine Platform
Positive
Dec 17, 2025
BioNxt Solutions Inc. has secured a final patent grant from the Eurasian Patent Organization for its sublingual thin-film cladribine platform, marking a significant milestone in its strategic global intellectual property expansion. The patent, val...
Business Operations and StrategyProduct-Related Announcements
BioNxt Unveils Innovative Oral Film to Transform MS Treatment
Positive
Dec 17, 2025
BioNxt Solutions is advancing its proprietary ‘Melt in Your Mouth’ cladribine film for multiple sclerosis (MS) patients who struggle with swallowing tablets, a common but under-recognized issue known as dysphagia. By offering this inno...
Business Operations and StrategyProduct-Related Announcements
BioNxt Secures Eurasian Patent Readiness for Sublingual Drug Delivery
Positive
Nov 4, 2025
BioNxt Solutions Inc. has received a ‘Readiness to Grant’ notification from the Eurasian Patent Organization for its patent application on sublingual delivery of anticancer drugs, specifically for treating autoimmune neurodegenerative ...
Business Operations and StrategyProduct-Related Announcements
BioNxt Secures European Patent for Innovative MS Treatment
Positive
Nov 4, 2025
BioNxt Solutions Inc. has received an ‘Intention to Grant’ notification from the European Patent Office for its sublingual thin-film formulation of cladribine, aimed at treating multiple sclerosis and related diseases. This patent, alo...
Business Operations and StrategyPrivate Placements and Financing
BioNxt Solutions Completes Debt Settlement to Strengthen Financial Position
Positive
Nov 4, 2025
BioNxt Solutions Inc. has successfully completed a debt settlement with an arm’s length creditor, resolving $225,010 in debt through the issuance of 112,505 common shares and a cash payment of $112,505. This strategic move helps BioNxt manag...
Business Operations and StrategyProduct-Related Announcements
BioNxt Solutions Advances Cladribine Formulation with New Study
Positive
Nov 4, 2025
BioNxt Solutions has initiated a large-mass animal bioequivalence study for its lead product, BNT23001, a sublingual Cladribine formulation for multiple sclerosis treatment. This study aims to optimize dosing parameters for an upcoming human bioeq...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.